Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 21, 2014; 20(11): 3025-3032
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.3025
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.3025
Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis
Jian He, Zhao-Chong Zeng, Zuo-Lin Xiang, Ping Yang, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Author contributions: He J and Zeng ZC designed the research; He J and Xiang ZL performed the research; Yang P contributed new reagents and analytic tools; He J and Zeng ZC analyzed the data; He J, Zeng ZC, Xiang ZL and Yang P wrote the paper.
Supported by the Medical Guidance Program of the Science and Technology Commission of Shanghai Municipality, No. 10411962400
Correspondence to: Zhao-Chong Zeng, Professor, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. zeng.zhaochong@zs-hospital.sh.cn
Telephone: +86-21-64041990 Fax: +86-21-64041990
Received: August 21, 2013
Revised: December 5, 2013
Accepted: January 2, 2014
Published online: March 21, 2014
Revised: December 5, 2013
Accepted: January 2, 2014
Published online: March 21, 2014
Core Tip
Core tip: Advances in the diagnosis and treatment of hepatocellular carcinoma (HCC) and extension of overall survival rates have led to an increase in the incidence of bone metastasis of HCC, which accounts for approximately 38.5% of all cases of extrahepatic metastasis of HCC. The patient’s quality of life would significantly be affected by the time of diagnosis. However, early diagnostic molecular markers for bone metastasis from HCC have not yet been identified. In this study, we performed differential serum peptide profiling in HCC patients with bone metastasis, which can be used for early prediction of this disorder.